Inogen, Inc.
Moat Score — Inogen, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Inogen holds device patents on its Inogen One/Rove portable concentrator line, FDA clearance for the Simeox airway-clearance device, and the Inogen Connect companion software, giving it real but not category-defining intellectual property versus larger diversified medtech rivals. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Inogen is a mid-sized device maker competing against both larger manufacturers and HME providers with their own scale; the filing gives no indication of a structural manufacturing cost advantage over rivals like Caire Medical or Drive DeVilbiss. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Pricing for the direct-to-consumer cash-sale channel carries some flexibility, but the rental and HME-provider channels are substantially constrained by Medicare/Medicaid reimbursement schedules, limiting overall pricing power across roughly 70% of the business. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Oxygen concentrator and respiratory-device sales carry no network effect; the value of a device to one patient does not increase because other patients also use Inogen products. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | The direct-to-consumer rental model requires national accreditation, state licensure, and Medicare billing privileges that competitors mostly lack, meaning patients and referring physicians already in Inogen's rental/billing ecosystem face real friction switching to a provider without that same regulatory infrastructure. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The portable oxygen concentrator and broader respiratory-device market supports multiple manufacturers (Caire Medical, Drive DeVilbiss, Rhythm Healthcare) and providers (Lincare, Apria, AdaptHealth) simultaneously, so it is not a naturally scale-limited niche, even though Philips Respironics' 2024 exit modestly reduced competitive density. |